NCT01881217 is a Phase 1 clinical trial of BAY1179470 in Neoplasms, sponsored by Bayer.

Who is sponsoring NCT01881217?

NCT01881217 is sponsored by Bayer.

What drugs are being tested in NCT01881217?

Interventions in NCT01881217: BAY1179470.

Is NCT01881217 still recruiting?

NCT01881217 is currently completed. Last updated 14 September 2017.

Last reviewed 2017-09-14 · How we verify

NCT01881217

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

First-in-man Dose Escalation Study of BAY1179470 in Patients With Advanced, Refractory Solid Tumors

Completed Phase 1 Last updated 14 September 2017

What this trial tests

Phase 1 trial testing BAY1179470 in Neoplasms in 35 participants. Completed in 16 August 2016.

Timeline

28 June 2013

Primary endpoint
18 March 2016

16 August 2016

Quick facts

Lead sponsor	Bayer
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	35
Start date	28 June 2013
Primary completion	18 March 2016
Estimated completion	16 August 2016
Sites	8 locations across Singapore, Japan, South Korea

Drugs / interventions tested

BAY1179470 — full drug profile →

Conditions studied

Neoplasms — all drugs for Neoplasms →

Sponsor

Bayer — full company profile →

Who can join

20 and older, any sex, with Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

An open-label, non-randomized, Phase I dose-escalation study designed to assess the safety, tolerability, pharmacokinetics(PK) /pharmacodynamics( PD) and tumor response profile of BAY1179470 in subjects with advanced, refractory solid tumors

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

FGF/FGFR signaling in health and disease.
Xie Y, Su N, Yang J, Tan Q, et al · · 2020 · cited 588× · PMID 32879300 · DOI 10.1038/s41392-020-00222-7
Molecular and clinical significance of fibroblast growth factor 2 (FGF2 /bFGF) in malignancies of solid and hematological cancers for personalized therapies.
Akl MR, Nagpal P, Ayoub NM, Tai B, et al · · 2016 · cited 148× · PMID 27007053 · DOI 10.18632/oncotarget.8203
FGFR3-TACC3 fusion in solid tumors: mini review.
Costa R, Carneiro BA, Taxter T, Tavora FA, et al · · 2016 · cited 107× · PMID 27409839 · DOI 10.18632/oncotarget.10482
The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets.
Chong DQ, Zhu AX. · · 2016 · cited 81× · PMID 27102149 · DOI 10.18632/oncotarget.8775
Structure, activation and dysregulation of fibroblast growth factor receptor kinases: perspectives for clinical targeting.
Farrell B, Breeze AL. · · 2018 · cited 77× · PMID 30545934 · DOI 10.1042/bst20180004
Current biologics for treatment of biliary tract cancers.
Zhao DY, Lim KH. · · 2017 · cited 25× · PMID 28736630 · DOI 10.21037/jgo.2017.05.04
Therapeutic Targeting of FGFR Signaling in Head and Neck Cancer.
Wang Z, Anderson KS. · · 2022 · cited 22× · PMID 36165723 · DOI 10.1097/ppo.0000000000000615
The Complexity and Significance of Fibroblast Growth Factor (FGF) Signaling for FGF-Targeted Cancer Therapies.
Nguyen AL, Facey COB, Boman BM. · · 2024 · cited 13× · PMID 39796710 · DOI 10.3390/cancers17010082

Verify or expand the search:

Other recruiting trials for Neoplasms

Currently open trials in the same condition.

NCT07438782 — First Time in Human (FTIH) Study to Investigate the Safety and Preliminary Activity of GSK5533524 Alone or in Combinatio · Phase 1 · recruiting
NCT07382817 — Phase 1 Study of JV-394 Autologous Anti-CD94 CAR T for r/r CD94+ T/NK Cell Neoplasms · Phase 1 · recruiting
NCT07277270 — A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tum · Phase 1 · recruiting
NCT07257640 — IL-5 CAR-T Cell Therapy for Refractory/Relapsed Eosinophilic Leukemia · Phase 1 · recruiting
NCT07213609 — A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer · Phase 1, PHASE2 · recruiting

Other Bayer trials

Trials by the same sponsor.

NCT05900388 — A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolis · not yet recruiting
NCT07490431 — An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Sympt · not yet recruiting
NCT05477953 — An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About · not yet recruiting
NCT07192952 — A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Child · Phase 3 · not yet recruiting
NCT07450599 — A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Befo · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01881217 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bayer
Last refreshed: 14 September 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01881217.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing